Vor Biopharma Inc. (VOR) — Financial statements
Income statement, balance sheet, and cash flow for Vor Biopharma Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00↓100.0% | 3↓61.0% | 9 | 0.00 | |
| Gross Profit | 0.00 | 0.00↑100.0% | -3↑61.0% | -9 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 322↑244.6% | 93↓1.1% | 94↑46.1% | 65↑35.8% | 48 | |
| General & Administrative Expenses | 50↑79.8% | 28↓12.1% | 32 | 0.00↓100.0% | 21 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 50↑79.8% | 28↓12.1% | 32↑59.3% | 20↓7.4% | 21 | |
| Other Expenses | 0.00 | 0.00↑100.0% | -3 | 0.00 | 0.00 | |
| Operating Expenses | 372↑206.7% | 121↓1.1% | 123↑45.1% | 84↑22.4% | 69 | |
| Total Costs & Expenses | 372↑206.7% | 121↓3.8% | 126↑34.9% | 93↑35.4% | 69 | |
| Operating Results | ||||||
| Operating Income | -372↓206.7% | -121↑3.8% | -126↓34.9% | -93↓35.4% | -69 | |
| Depreciation & Amortization | 3↓18.2% | 4↑1.0% | 3↓61.0% | 9↑524.8% | 1 | |
| EBITDA | -369↓213.4% | -118↓2.9% | -114↓37.6% | -83↓23.0% | -68 | |
| EBIT | -372↓206.7% | -121↓2.8% | -118↓28.0% | -92↓33.4% | -69 | |
| Interest & Other Income | ||||||
| Net Interest Income | 6↑37.4% | 4↓47.7% | 8↑517.3% | 1↑1012.6% | 0.12 | |
| Interest Income | 6↑37.4% | 4↓47.7% | 8↑517.3% | 1↑1012.6% | 0.12 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00↑100.0% | -8↓517.3% | -1 | 0.00 | |
| Other Income / Expenses | -324↓7694.0% | 4↓47.7% | 8↑517.3% | 1↑1012.6% | 0.12 | |
| Income Before Tax | -696↓495.3% | -117↑0.8% | -118↓28.0% | -92↓33.7% | -69 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -696↓495.3% | -117↑0.8% | -118↓28.0% | -92↓33.7% | -69 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -696↓495.3% | -117↑0.8% | -118↓28.0% | -92↓33.7% | -69 | |
| Bottom-Line Net Income | -696↓495.3% | -117↑0.8% | -118↓28.0% | -92↓31.3% | -70 | |
| EPS (Basic) | -70.50↓107.4% | -34.00↑2.9% | -35.00↑24.9% | -46.60↓23.3% | -37.80 | |
| EPS (Diluted) | -70.50↓107.4% | -34.00↑2.9% | -35.00↑24.9% | -46.60↓23.3% | -37.80 | |
| Weighted Average Shares | 10↑187.4% | 3↑2.3% | 3↑69.9% | 2↑6.4% | 2 | |
| Weighted Average Diluted Shares | 10↑187.4% | 3↑2.3% | 3↑69.9% | 2↑6.4% | 2 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.